의약품 지질 기반 부형제 시장 : 규모, 점유율 및 동향 분석 보고서 - 부형제 유형별, 제품 용도별, 질환 용도별, 산업 용도별, 연령층별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Pharmaceutical Lipid-based Excipients Market Growth & Trends:

The global pharmaceutical lipid-based excipients market size is anticipated to reach USD 2.42 billion by 2030 and is anticipated to expand at a CAGR of 4.8% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of poorly soluble drug candidates, representing 87% of pipeline candidates, has driven the adoption of advanced excipient solutions. Lipid-based excipients such as solid lipid nanoparticles and self-emulsifying drug delivery systems have become essential for complex molecules, addressing formulation challenges effectively. This surge reflects the pharmaceutical industry's need for innovative solutions to enhance drug bioavailability and efficacy.

The integration of lipid-based excipients has revolutionized mRNA vaccines and gene therapies, as highlighted during the COVID-19 pandemic. Moreover, the demand for cost-effective excipients has further increased due to patent expirations for major pharmaceutical drugs. These factors underscore the transformative impact of lipid excipients on modern pharmaceutical development and their role in driving innovation in drug delivery.

Advancements in artificial intelligence (AI) and formulation technologies further contribute to the growth of the lipid excipients market. AI-driven modeling accelerates lipid based formulations, enhancing predictability and reducing time-to-market. Regulatory bodies maintain high expectations for lipid excipients, prioritizing patient safety by focusing on purity and safety characteristics, ultimately ensuring the quality and effectiveness of pharmaceutical products.

Pharmaceutical Lipid-based Excipients Market Report Highlights:

• Based on excipients, oil excipients dominated the market in 2024, accounting for 40.5% of the total revenue due to advancements in lipid drug delivery, nutraceutical use, and demand for sustainable ingredients.
• The lecithin and phospholipids segment is projected to grow at a robust CAGR over the forecast period.
• Based on product applications, topical formulations led the market with the largest revenue share in 2024; however, ophthalmic applications are expected to grow at the fastest rate of 6.7% over the forecast period.
• Based on disease, oncological applications of lipid-based excipients garnered the largest revenue in 2024, aided by a growing pipeline of targeted therapies and immunotherapies for cancer.
• Based on industry, the nutraceutical (dietary supplements & others) segment is expected to witness the fastest CAGR over the forecast period, fueled by strategic partnerships between lipid excipient manufacturers and supplement-focused pharmaceutical companies.
• As aging-related conditions become more widespread, the geriatric products (65+ years) segment is expected to witness the fastest CAGR of over 5.0% over the forecast period.
• Based on end use, pharmaceutical manufacturers emerged as dominant end users in the market in 2024, accounting for 64.9% of the total revenue.
• In April 2024, IOI Oleo GmbH launched DYNASAN CrystalCONTROL L for the cosmetics industry. This product addresses the "blooming" effect in stick formulations, improving product stability and aesthetics for a worry-free process globally.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation
  • 1.1.1 Regional Scope
  • 1.1.2 Estimates And Forecast Timeline
  • 1.1.3 Objectives
  • 1.1.4 Objective - 1
  • 1.1.5 Objective - 2
  • 1.1.6 Objective - 3
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Market Evaluation Methodology:
• 1.7 List Of Secondary Sources
• 1.8 List of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot (Regional)
• 2.2 Segment Snapshot (Excipient Type)
• 2.3 Segment Snapshot (Product Application)
• 2.4 Segment Snapshot (Disease Application)
• 2.5 Segment Snapshot (Product Industry & Age-based Product)
• 2.6 Segment Snapshot (Product Industry & Age-based Product)
• 2.7 Segment Snapshot (End-use)
• 2.8 Competitive Landscape

Chapter 3 Manufacturers Perspective: Market Variables, Trends, and Scope

• 3.1 Pharmaceutical Lipid-Based Excipients Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
    • 3.1.1.1 Excipient Market
  • 3.1.2 Ancillary Market Outlook
    • 3.1.2.1 Polymers Excipient Market
    • 3.1.2.2 Sugars Excipient Market
    • 3.1.2.3 Minerals Excipient Market
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Proliferation of Drug Candidates with Low Water Solubility and Bioavailability Challenges
    • 3.2.1.2 Growing Application of Lipid Excipients in Biologics and RNA-based Therapeutics
    • 3.2.1.3 Impact of Patent Expirations on Generic Drug Production and Lipid Excipients Demand
  • 3.2.2 Market Opportunities Analysis
    • 3.2.2.1 Expansion of Pharmaceutical Manufacturing in Emerging Markets as a Growth Opportunity for Lipid Excipients
    • 3.2.2.2 Growth of Local Manufacturers Enhancing Competition and Innovation in the Lipid Excipients Market
  • 3.2.3 Market Restraint Analysis
    • 3.2.3.1 Price Sensitivity in Emerging Markets Restricting the Adoption of Premium Lipid Excipients
    • 3.2.3.2 Market Dominance by Key Players Restricting Entry and Innovation in Lipid Excipients Sector
  • 3.2.4 Market Challenges Analysis
    • 3.2.4.1 Substantial R&D Investment Requirements for Developing Novel Lipid Excipients and Delivery Systems
    • 3.2.4.2 Global Regulatory and Compliance Complexities Adding Operational Challenges for Lipid Excipients Manufacturers
• 3.3 Pharmaceutical Lipid-Based Excipients Market Analysis Tools
  • 3.3.1 PORTER'S Five Forces Analysis
• 3.4 Customer Needs, Pains, and Gains Analysis

Chapter 4 Manufacturers Competitive Landscape of Lipid-based Excipients

• 4.1 Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
• 4.2 Company Profiles for Manufacturers of Lipid Excipients
  • 4.2.1 ABITEC (ABF INGREDIENTS).
    • 4.2.1.1 Company Overview
    • 4.2.1.2 Financial Overview
    • 4.2.1.3 Product Overview
    • 4.2.1.4 Key Strategic initiatives
  • 4.2.2 BASF CORPORATION
    • 4.2.2.1 Company Overview
    • 4.2.2.2 Financial Overview
    • 4.2.2.3 Product Overview
    • 4.2.2.4 Strategic Initiatives
  • 4.2.3 GATTEFOSSE
    • 4.2.3.1 Company Overview
    • 4.2.3.2 Financial Overview
    • 4.2.3.3 Product Overview
    • 4.2.3.4 Strategic Initiatives
  • 4.2.4 CORDENPHARMA
    • 4.2.4.1 Company Overview
    • 4.2.4.2 Financial Overview
    • 4.2.4.3 Product Overview
    • 4.2.4.4 Strategic Initiatives
  • 4.2.5 LIPOID GMBH
    • 4.2.5.1 Company Overview
    • 4.2.5.2 Financial Overview
    • 4.2.5.3 product Overview
    • 4.2.5.4 Key Strategic Initiatives
  • 4.2.6 IOI OLEO GMBH
    • 4.2.6.1 Company overview
    • 4.2.6.2 Financial Overview
    • 4.2.6.3 Product Overview
    • 4.2.6.4 Strategic initiatives
  • 4.2.7 CRODA INTERNATIONAL PLC
    • 4.2.7.1 Company Overview
    • 4.2.7.2 Financial Overview
    • 4.2.7.3 Product Overview
    • 4.2.7.4 Strategic Initiatives
  • 4.2.8 EVONIK INDUSTRIES AG
    • 4.2.8.1 Company Overview
    • 4.2.8.2 Financial Overview
    • 4.2.8.3 Product Overview
    • 4.2.8.4 Strategic Initiatives
  • 4.2.9 ASHLAND
    • 4.2.9.1 Company Overview
    • 4.2.9.2 Financial Overview
    • 4.2.9.3 Product Overview
    • 4.2.9.4 Strategic Initiatives
  • 4.2.10 MERCK KGAA
    • 4.2.10.1 Company Overview
    • 4.2.10.2 Financial Overview: Thermo Fisher Scientific
    • 4.2.10.3 Product Overview
    • 4.2.10.4 Strategic Initiatives
• 4.3 Company Market Share Analysis, 2024
• 4.4 Heatmap analysis

Chapter 5 End User Perspective: Market Variables, Trends, and Scope

• 5.1 Pharmaceutical Lipid-Based Excipients Market Outlook - End User (Buyer/Consumer Companies) Perspective
  • 5.1.1 Market Driver Analysis
    • 5.1.1.1 Innovation in formulation development
    • 5.1.1.2 End user companies are formulating drugs for pediatric, geriatric, and chronic disease markets
    • 5.1.1.3 The Influence of ESG Objectives on the Adoption of Sustainable Lipid Excipients by End Users
  • 5.1.2 Market Opportunities Analysis
    • 5.1.2.1 Impact of Patent Expirations on Generic Drug Production and Lipid Excipients Demand
    • 5.1.2.2 Increasing prevalence of chronic diseases driving demand for lipid based formulations
  • 5.1.3 Market Restraint Analysis
    • 5.1.3.1 High R&D Costs, a Restraint for end use Pharmaceutical Companies Using Lipid-Based Excipients
    • 5.1.3.2 Regulatory Complexity
  • 5.1.4 Market Challenges Analysis
    • 5.1.4.1 Incompatibility with the active pharmaceutical ingredient (API)
    • 5.1.4.2 Stability and Shelf-Life Concerns
• 5.2 Pharmaceutical Lipid-Based Excipients Market Analysis Tools
  • 5.2.1 PORTER'S Five Forces Analysis

Chapter 6 End User Analysis (Buyer/Consumer Companies) Competitive Landscape

• 6.1 Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
• 6.2 Buyer/Consumer Company Profiles
  • 6.2.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 6.2.1.1 Company Overview
    • 6.2.1.2 Financial Overview
    • 6.2.1.3 Product Overview
    • 6.2.1.4 Key Strategic initiatives
  • 6.2.2 VIATRIS INC. (FORMERLY MYLAN)
    • 6.2.2.1 Company Overview
    • 6.2.2.2 Financial Overview
    • 6.2.2.3 PRODUCT OVERVIEW
    • 6.2.2.4 Strategic Initiatives
  • 6.2.3 SANDOZ (A DIVISION OF NOVARTIS)
    • 6.2.3.1 Company Overview
    • 6.2.3.2 Financial Overview
    • 6.2.3.3 Product Overview
  • 6.2.4 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 6.2.4.1 Company Overview
    • 6.2.4.2 Financial Overview
    • 6.2.4.3 Product Overview
  • 6.2.5 CIPLA LTD.
    • 6.2.5.1 Company Overview
    • 6.2.5.2 Financial Overview
    • 6.2.5.3 product Overview
    • 6.2.5.4 Key Strategic Initiatives
  • 6.2.6 DR. REDDY'S LABORATORIES LTD.
    • 6.2.6.1 Company overview
    • 6.2.6.2 Financial Overview
    • 6.2.6.3 Product Overview
    • 6.2.6.4 Strategic initiatives
  • 6.2.7 AUROBINDO PHARMA LTD.
    • 6.2.7.1 Company Overview
    • 6.2.7.2 Financial Overview
    • 6.2.7.3 Product Overview
    • 6.2.7.4 Strategic Initiatives
  • 6.2.8 LUPIN LTD.
    • 6.2.8.1 Company Overview
    • 6.2.8.2 Financial Overview
    • 6.2.8.3 Product Overview
  • 6.2.9 ZYDUS LIFESCIENCES LTD. (FORMERLY CADILA)
    • 6.2.9.1 Company Overview
    • 6.2.9.2 Financial Overview
    • 6.2.9.3 Product Overview
    • 6.2.9.4 Strategic Initiatives
  • 6.2.10 HIKMA PHARMACEUTICALS PLC
    • 6.2.10.1 Company Overview
    • 6.2.10.2 Financial Overview: Hikma Pharmaceuticals PLC
    • 6.2.10.3 Product Overview
• 6.3 Heatmap analysis

Chapter 7 Pharmaceutical Lipid-Based Excipients Market, By Excipient Type, 2018 - 2030 (USD Million)

• 7.1 Pharmaceutical Lipid-Based Excipients Market: Excipient Type Analysis
• 7.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Excipient Type, 2018 - 2030 (USD Million)
  • 7.2.1 Oils
    • 7.2.1.1 Sesame Oil
    • 7.2.1.2 Soybean Oil
    • 7.2.1.3 Sunflower Oil
    • 7.2.1.4 Linseed Oil /Flaxseed Oil
    • 7.2.1.5 Safflower Oil
    • 7.2.1.6 Coconut Oil
    • 7.2.1.7 Arachis Oil / Peanut Oil
    • 7.2.1.8 Corn Oil / Maize Oil
    • 7.2.1.9 Olive Oil
    • 7.2.1.10 Almond Oil
    • 7.2.1.11 Castor Oil
    • 7.2.1.12 Cotton Seed Oil
    • 7.2.1.13 Grapeseed Oil
    • 7.2.1.14 Other Oils
  • 7.2.2 Hydrogenated Vegetable Oils
  • 7.2.3 GMCC
  • 7.2.4 Hard Fats
  • 7.2.5 Medium Chain Triglycerides (MCTS)
  • 7.2.6 Lecithin And Phospholipids
  • 7.2.7 Sodium Oleate
  • 7.2.8 Capri Caprylic Mono Diglyceride
  • 7.2.9 Other Excipient Types

Chapter 8 Pharmaceutical Lipid-Based Excipients Market, By Product Applications, 2018 - 2030 (USD Million)

• 8.1 Pharmaceutical Lipid-Based Excipients Market: Product Application Analysis
• 8.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Product Application, 2018 - 2030 (USD Million)
  • 8.2.1 Oral Formulations
    • 8.2.1.1 Softgel Capsules
    • 8.2.1.2 Solid Dosage
    • 8.2.1.3 Liquid Oral
    • 8.2.1.4 Solid Lipid Nanoparticles (Slns)
  • 8.2.2 Parenteral
    • 8.2.2.1 Small Volume Parenteral
    • 8.2.2.2 Large Volume Parenteral
  • 8.2.3 Topical Applications
    • 8.2.3.1 Creams
    • 8.2.3.2 Ointments
    • 8.2.3.3 Other Topical Applications
  • 8.2.4 Ophthalmic Applications
    • 8.2.4.1 Eye Drops
    • 8.2.4.2 Ocular Emulsions
  • 8.2.5 Suppositories
    • 8.2.5.1 Rectal Suppositories
    • 8.2.5.2 Vaginal Suppositories
    • 8.2.5.3 Other Suppositories
  • 8.2.6 Other Product Applications

Chapter 9 Pharmaceutical Lipid-Based Excipients Market, By Disease Application, 2018 - 2030 (USD Million)

• 9.1 Pharmaceutical Lipid-Based Excipients Market: Disease Application Analysis
• 9.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Disease Application, 2018 - 2030 (USD Million)
  • 9.2.1 Cardiovascular Diseases
  • 9.2.2 Neurological Disorders
  • 9.2.3 Oncology
  • 9.2.4 Metabolic Disorders
  • 9.2.5 Hormonal Therapies
  • 9.2.6 Infectious Diseases
  • 9.2.7 Other Disease Applications

Chapter 10 Pharmaceutical Lipid-Based Excipients Market, By Product Industry, 2018 - 2030 (USD Million)

• 10.1 Pharmaceutical Lipid-Based Excipients Market: Product Industry Analysis
• 10.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Product Industry, 2018 - 2030 (USD Million)
  • 10.2.1 Pharmaceutical (OTC & RX)
  • 10.2.2 Nutraceutical (Dietary Supplements & Other)

Chapter 11 Pharmaceutical Lipid-Based Excipients Market, By Age-Based Product, 2018 - 2030 (USD Million)

• 11.1 Pharmaceutical Lipid-Based Excipients Market: Age-Based Product Analysis
• 11.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by Age-Based Product, 2018 - 2030 (USD Million)
  • 11.2.1 Pediatric Products (0-18 Years)
  • 11.2.2 Adult Products (19-64 Years)
  • 11.2.3 Geriatric Products (65+ Years)

Chapter 12 Pharmaceutical Lipid-Based Excipients Market, By End-Use, 2018 - 2030 (USD Million)

• 12.1 Pharmaceutical Lipid-Based Excipients Market: End-Use Product Analysis
• 12.2 Pharmaceutical Lipid-Based Excipients Market, Estimates & Forecast by End-Use, 2018 - 2030 (USD Million)
  • 12.2.1 Pharmaceutical Manufacturers
  • 12.2.2 Contract Development And Manufacturing Organizations (CDMOS)
  • 12.2.3 Other

Chapter 13 Pharmaceutical Lipid-Based Excipients Market: Regional Estimates and Trend Analysis

• 13.1 Pharmaceutical Lipid-Based Excipients Market: Regional Outlook
• 13.2 North America
  • 13.2.1 North America Pharmaceutical Lipid-Based Excipients Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.2.2 U.S.
    • 13.2.2.1 Key Country Dynamics
    • 13.2.2.2 U.S. Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 13.2.2.3 Competitive/Market Scenario
    • 13.2.2.4 Regulatory Framework
  • 13.2.3 Canada
    • 13.2.3.1 Key Country Dynamics
    • 13.2.3.2 Canada Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 13.2.3.3 Competitive/Market Scenario
    • 13.2.3.4 Regulatory Framework
  • 13.2.4 Mexico
    • 13.2.4.1 Key Country Dynamics
    • 13.2.4.2 Mexico Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.2.4.3 Competitive/Market Scenario
    • 13.2.4.4 Regulatory Framework
• 13.3 Europe
  • 13.3.1 Europe Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.3.2 UK
    • 13.3.2.1 Key Country Dynamics
    • 13.3.2.2 UK pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.2.3 Competitive/Market Scenario
    • 13.3.2.4 Regulatory Framework
  • 13.3.3 Germany
    • 13.3.3.1 Key Country Dynamics
    • 13.3.3.2 Germany pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.3.3 Competitive/Market Scenario
    • 13.3.3.4 Regulatory Framework
  • 13.3.4 France
    • 13.3.4.1 Key Country Dynamics
    • 13.3.4.2 France pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.4.3 Competitive/Market Scenario
    • 13.3.4.4 Regulatory Framework
  • 13.3.5 Italy
    • 13.3.5.1 Key Country Dynamics
    • 13.3.5.2 Italy pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.5.3 Competitive/Market Scenario
    • 13.3.5.4 Regulatory Framework
  • 13.3.6 Spain
    • 13.3.6.1 Key Country Dynamics
    • 13.3.6.2 Spain pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.6.3 Competitive/Market Scenario
    • 13.3.6.4 Regulatory Framework
  • 13.3.7 Norway
    • 13.3.7.1 Key Country Dynamics
    • 13.3.7.2 Norway Pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.7.3 Competitive/Market Scenario
    • 13.3.7.4 Regulatory Framework
  • 13.3.8 Sweden
    • 13.3.8.1 Key Country Dynamics
    • 13.3.8.2 Sweden pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.3.8.3 Competitive/Market Scenario
    • 13.3.8.4 Regulatory Framework
  • 13.3.9 Denmark
    • 13.3.9.1 Key Country Dynamics
    • 13.3.9.2 Denmark Pharmaceutical lipid-based excipients market estimates and forecasts, 2018 - 2030 (USD Million)
    • 13.3.9.3 Competitive/Market Scenario
    • 13.3.9.4 Regulatory Framework
  • 13.3.10 Rest Of Europe Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 13.4 Asia Pacific
  • 13.4.1 Asia Pacific Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.4.2 China
    • 13.4.2.1 Key Country Dynamics
    • 13.4.2.2 China pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.4.2.3 Competitive/Market Scenario
    • 13.4.2.4 Regulatory Framework
  • 13.4.3 India
    • 13.4.3.1 Key Country Dynamics
    • 13.4.3.2 India pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.4.3.3 Competitive/Market Scenario
    • 13.4.3.4 Regulatory Framework
  • 13.4.4 South Korea
    • 13.4.4.1 Key Country Dynamics
    • 13.4.4.2 South Korea pharmaceutical lipid-based excipients Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 13.4.4.3 Competitive/Market Scenario
    • 13.4.4.4 Regulatory Framework
  • 13.4.5 Rest Of Asia Pacific Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 13.5 Latin America
  • 13.5.1 Latin America Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.5.2 Brazil
    • 13.5.2.1 Key Country Dynamics
    • 13.5.2.2 Brazil pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.5.2.3 Competitive/Market Scenario
    • 13.5.2.4 Regulatory Framework
  • 13.5.3 Argentina
    • 13.5.3.1 Key Country Dynamics
    • 13.5.3.2 Argentina pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.5.3.3 Competitive/Market Scenario
    • 13.5.3.4 Regulatory Framework
  • 13.5.4 Rest Of Latin America Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 13.6 MEA
  • 13.6.1 MEA Pharmaceutical Lipid-Based Excipients, Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 13.6.2 South Africa
    • 13.6.2.1 Key Country Dynamics
    • 13.6.2.2 South Africa Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.2.3 Competitive/Market Scenario
    • 13.6.2.4 Regulatory Framework
  • 13.6.3 Saudi Arabia
    • 13.6.3.1 Key Country Dynamics
    • 13.6.3.2 Saudi Arabia pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.3.3 Competitive/Market Scenario
    • 13.6.3.4 Regulatory Framework
  • 13.6.4 UAE
    • 13.6.4.1 Key Country Dynamics
    • 13.6.4.2 UAE pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.4.3 Competitive/Market Scenario
    • 13.6.4.4 Regulatory Framework
  • 13.6.5 Jordan
    • 13.6.5.1 Key Country Dynamics
    • 13.6.5.2 Jordan pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.5.3 Competitive/Market Scenario
    • 13.6.5.4 Regulatory Framework
  • 13.6.6 Egypt
    • 13.6.6.1 Key Country Dynamics
    • 13.6.6.2 Egypt pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.6.3 Competitive/Market Scenario
    • 13.6.6.4 Regulatory Framework
  • 13.6.7 Iran
    • 13.6.7.1 Key Country Dynamics
    • 13.6.7.2 Iran pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.7.3 Competitive/Market Scenario
    • 13.6.7.4 Regulatory Framework
  • 13.6.8 Kuwait
    • 13.6.8.1 Key Country Dynamics
    • 13.6.8.2 Kuwait pharmaceutical lipid-based excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 13.6.8.3 Competitive/Market Scenario
    • 13.6.8.4 Regulatory Framework
  • 13.6.9 Rest Of MEA Pharmaceutical Lipid-Based Excipients Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 14 Competitive Landscape

• 14.1. Market Participant Categorization
• 14.2. Company Market Position Analysis/ Heap Map Analysis
• 14.3. Strategy Mapping
  • 14.3.1. Mergers & Acquisitions
  • 14.3.2. Partnerships & Collaborations
  • 14.3.3. Others
• 14.4. Company Profiles
  • 14.4.1. ABITEC Corporation
  • 14.4.2. BASF
  • 14.4.3. Gattefosse
  • 14.4.4. CordenPharma
  • 14.4.5. Lipoid
  • 14.4.6. IOI Oleo GmbH
  • 14.4.7. Croda International
  • 14.4.8. Evonik Industries
  • 14.4.9. Ashland
  • 14.4.10. Merck KGaA